Squamous Cell Carcinoma

Oncology·MeSH: Carcinoma, Squamous Cell

Prevalence

14.0 / 100K

Incidence

6.0 / 100K/yr

136 drugs in development·59 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(39)
DrugCompany
5-flurouracilGH Research PLC (GHRS)
Ameluz®Biofrontera Inc. (BFRI)
amivantamabGH Research PLC (GHRS)
amivantamabGH Research PLC (GHRS)
avelumabCG Oncology, Inc. (CGON)
AZD5069ASTRAZENECA PLC (AZN)
AZD9150ASTRAZENECA PLC (AZN)
Camrelizumab and CetuximabFATE THERAPEUTICS INC (FATE)
Camrelizumab and ChemotherapyFATE THERAPEUTICS INC (FATE)
cemiplimab+fianlimab fixed dose combinationREGENERON PHARMACEUTICALS, INC. (REGN)
cetuximabGH Research PLC (GHRS)
cetuximabASTRAZENECA PLC (AZN)
CetuximabFATE THERAPEUTICS INC (FATE)
EGFR-TKI inhibitor based on investigator's choiceMerus N.V. (MRUS)
Erbitux®Amneal Pharmaceuticals, Inc. (AMRX)
Erbitux®FATE THERAPEUTICS INC (FATE)
fdc fianlimab+cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
ficerafusp alfa (formerly BCA101)Bicara Therapeutics Inc. (BCAX)
I-DXdMerck & Co., Inc. (MRK)
IfosfamideUNITED THERAPEUTICS Corp (UTHR)
Investigator's ChoiceMerus N.V. (MRUS)
LevoleucovorinMerck & Co., Inc. (MRK)
MCLA-158 (petosemtamab)Merus N.V. (MRUS)
MEDI4736ASTRAZENECA PLC (AZN)
MultikineCEL SCI CORP (CVM)
nbtxr3LianBio (LIANY)
ozuriftamab vedotinBioAtla, Inc. (BCAB)
pds0101PDS Biotechnology Corp (PDSB)
petosemtamabMerus N.V. (MRUS)
Petosemtamab (MCLA-158)Merus N.V. (MRUS)
platinum based chemotherapyGH Research PLC (GHRS)
regn15505+cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
retifanlimabIncyte Corp. (INCY)
rigosertibTRAWS PHARMA, INC. (ONTX)
rp1 in combination with nivolumabReplimune Group, Inc. (REPL)
RPH-002Amneal Pharmaceuticals, Inc. (AMRX)
RPH-002FATE THERAPEUTICS INC (FATE)
sugemalimabEQRx, Inc. (EQRX)
VolrustomigASTRAZENECA PLC (AZN)
Phase 2(41)
DrugCompany
AmivantamabStructure Therapeutics Inc. (GPCR)
Amivantamab and Recombinant Human HyaluronidaseStructure Therapeutics Inc. (GPCR)
Amivantamab and Recombinant Human HyaluronidaseFATE THERAPEUTICS INC (FATE)
Amivantamab IVStructure Therapeutics Inc. (GPCR)
Amivantamab SCStructure Therapeutics Inc. (GPCR)
cemiplimabWest Pharmaceutical Services Inc. (WST)
cemiplimabReplimune Group, Inc. (REPL)
CemiplimabELI LILLY & Co (LLY)
CemiplimabMerus N.V. (MRUS)
Cemiplimab 350 mg IVMerus N.V. (MRUS)
CetuximabStructure Therapeutics Inc. (GPCR)
cmp-001CHECKMATE PHARMACEUTICALS, INC. (CMPI)
cylembioIO Biotech, Inc. (IOBT)
domvanalimabGILEAD SCIENCES, INC. (GILD)
DostarlimabMerus N.V. (MRUS)
EOS-448iTeos Therapeutics, Inc. (ITOS)
fdc fianlimab+cemiplimabWest Pharmaceutical Services Inc. (WST)
FID-007Fulgent Genetics Inc. (FLGT)
FID007Fulgent Genetics Inc. (FLGT)
gedeptinGeoVax Labs, Inc. (GOVX)
GSK5764227Merus N.V. (MRUS)
had5-hpv vaccineImmunityBio, Inc. (IBRX)
incb099280Incyte Corp. (INCY)
ino-3112INOVIO PHARMACEUTICALS, INC. (INO)
LN-145ENANTA PHARMACEUTICALS INC (ENTA)
LN-145Filana Therapeutics Inc. (FLNA)
LN-145Merus N.V. (MRUS)
rp1Replimune Group, Inc. (REPL)
rtx-224Rubius Therapeutics, Inc. (RUBY)
Sacituzumab GovitecanFATE THERAPEUTICS INC (FATE)
sar444245Sanofi (SNY)
SerplulimabENANTA PHARMACEUTICALS INC (ENTA)
SetanaxibCalliditas Therapeutics AB (CALT)
si-b001NYMOX PHARMACEUTICAL CORP (NYMXF)
STRO-002 (luveltamab tazevibulin, luvelta)SUTRO BIOPHARMA, INC. (STRO)
versamune hpvPDS Biotechnology Corp (PDSB)
vidutolimodCHECKMATE PHARMACEUTICALS, INC. (CMPI)
vobramitamab duocarmazineMACROGENICS INC (MGNX)
Vobramitamab Duocarmazine (vobra duo)MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.0 mgMACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.7 mgMACROGENICS INC (MGNX)
Phase 1(36)
DrugCompany
18F-NOTA-ABY-030FATE THERAPEUTICS INC (FATE)
18F-NOTA-ABY-030Amneal Pharmaceuticals, Inc. (AMRX)
aldesleukinGH Research PLC (GHRS)
APR-1051Aprea Therapeutics, Inc. (APRE)
BI 770371Amneal Pharmaceuticals, Inc. (AMRX)
BI 770371FATE THERAPEUTICS INC (FATE)
BirinapantIGM Biosciences, Inc. (IGMS)
cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
CetuximabNEKTAR THERAPEUTICS (NKTR)
CIML NK cell InfusionAmneal Pharmaceuticals, Inc. (AMRX)
CIML NK cell InfusionFATE THERAPEUTICS INC (FATE)
CLD-201 (SuperNova™ / SNV1)Calidi Biotherapeutics Inc. (CLDI)
cosibelimabCheckpoint Therapeutics, Inc. (CKPT)
gen-011GENOCEA BIOSCIENCES, INC. (GNCA)
IDE034IDEAYA Biosciences, Inc. (IDYA)
Interleukin-15 SuperagonistAmneal Pharmaceuticals, Inc. (AMRX)
Interleukin-15 SuperagonistFATE THERAPEUTICS INC (FATE)
jnj-90301900JOHNSON & JOHNSON (JNJ)
jnj-90301900Innovation Pharmaceuticals Inc. (IPIX)
NKTR-0165NEKTAR THERAPEUTICS (NKTR)
NKTR-255NEKTAR THERAPEUTICS (NKTR)
NKTR-288NEKTAR THERAPEUTICS (NKTR)
NKTR-422NEKTAR THERAPEUTICS (NKTR)
nogapendekin alfa inbakiceptImmunityBio, Inc. (IBRX)
ph-762Phio Pharmaceuticals Corp. (PHIO)
Polymer-conjugated IL-15 Receptor Agonist NKTR-255NEKTAR THERAPEUTICS (NKTR)
RP3Replimune Group, Inc. (REPL)
sl-279252Shattuck Labs, Inc. (STTK)
STRO-001SUTRO BIOPHARMA, INC. (STRO)
STRO-003SUTRO BIOPHARMA, INC. (STRO)
STRO-004SUTRO BIOPHARMA, INC. (STRO)
stro-006SUTRO BIOPHARMA, INC. (STRO)
stro-227SUTRO BIOPHARMA, INC. (STRO)
tagmokitugCoherus Oncology, Inc. (CHRS)
tbio-4101GH Research PLC (GHRS)
zimberelimabGILEAD SCIENCES, INC. (GILD)

Compare drugs

hydroxyurea vs Tyvythydroxyurea vs unloxcythydroxyurea vs 5-flurouracil

Frequently asked questions

How many drugs are in development for Squamous Cell Carcinoma?

BioSniper tracks 136 drugs in development for Squamous Cell Carcinoma across 59 companies.

How many clinical trials target Squamous Cell Carcinoma?

There are 8 clinical trials targeting Squamous Cell Carcinoma tracked by BioSniper.

What is the prevalence of Squamous Cell Carcinoma?

The estimated prevalence of Squamous Cell Carcinoma is approximately 14.0 per 100,000 population.

Deep-dive into Squamous Cell Carcinoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Squamous Cell Carcinoma — Drugs in Development & Clinical Trials | BioSniper